PD-1/PD-L1抑制剂在晚期胃癌治疗中的临床应用进展  

Progress in the clinical application of PD-1/PD-L1 inhibitors in the treatment of advanced gastric cancer

作　　者：石磊[1] 贾秋红[1] 刘福建[1] Shi Lei,Jia Qiuhong,Liu Fujian(Digestive Department,the People＇s Hospital of Guigang City,Guangxi,53710)

机构地区：[1]贵港市人民医院消化内科,广西537100

出　　处：《中国社区医师》2018年第16期5-6,共2页Chinese Community Doctors

摘　　要：胃癌是一种临床常见恶性肿瘤,具有较强的转移、浸润能力,患者预后普遍较差。当前,随着医疗科技的飞速发展,该病的手术治疗效果有了显著提高,放疗、化疗等辅助性治疗也取得了相应的进展,但是上述治疗手段对于晚期胃癌的治疗效果一般。程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)免疫靶点治疗对肿瘤细胞的转移具有良好的抑制效果,增强T细胞的活性,起到免疫杀伤肿瘤细胞的作用。本文主要针对PD-1/PD-L1抑制剂在晚期胃癌治疗中的应用效果展开综述。Gastric cancer is a common malignant tumor,with a strong ability of metastasis and infiltration,and the prognosis of the patients is generally poor.At present,with the rapid development of medical science and technology,the effect of the surgical treatment of the disease has been greatly improved,adjuvant therapy,and radiotherapy and chemotherapy have also made corresponding progress.However,the therapeutic effect of these treatments on advanced gastric cancer is general.Programmed death receptor-1（PD-1）/Programmed death ligand-1（PD-L1） immunologic target therapy has a good inhibitory effect on the metastasis of tumor cells.It can enhance the activity of T cells and play the role of immune killing tumor cells.The application of PD-1/PD-L1 inhibitors in the treatment of advanced gastric cancer is reviewed in this paper.

关 键 词：PD-1/PD-L1 胃癌 临床治疗 

分 类 号：R735.2[医药卫生—肿瘤]